PAREXEL® CONSULTING

BETTER PROOF THROUGH PLANNING

New paths to commercialization.

NOVEMBER/DECEMBER

As reimbursement and access become more challenging to secure, trial design and evidence generation for new drugs must evolve to reflect clinical, regulatory, and commercial mandates. In this update, we look at designing trial endpoints that speak to multiple stakeholder needs both now and into the future, as well as determine the potential value of an asset before significant investment.

Written by Barry Farrimond, Vice President, Pricing & Market Access, this article gives you specifics about often unexpected trial data that payers now require from drug developers to assure reimbursements.

Ask the AuthorNovember 18th @ 11:30am EST

Have questions about our article "Designing Trials Payer Can Trust"? Send us your questions and the author Barry Farrimond will answer them in a Podcast on Nov. 18th. Please send us your questions by November 7th. Any questions not answered during the podcast will be answered and distributed to all attendees after the event.